Lutetium Lu 177 Dotatate Approved by FDA.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-021
Abstract: The FDA recently approved the radiopharmaceutical lutetium Lu 177 dotatate to treat patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The approval was based on results of the phase III NETTER-1 trial. read more here.
Keywords: approved fda; 177 dotatate; dotatate approved; lutetium 177 ... See more keywords